Abstract:Background: Nanoparticles exhibit distinct behaviours within the body, depending on their physicochemical properties and administration routes. However, in vivo behaviour of poly(lactic-co-glycolic acid) (PLGA) nanoparticles, especially when administered nasally, remains unexplored; furthermore, there is a lack of comparative analysis of uptake efficiency among different administration routes. Therefore, here, we aimed to comprehensively investigate the real-time in vivo behaviour of PLGA nanoparticles across various administration routes. PLGA-NH2 nanoparticles of three sizes were synthesised using an oil-in-water single-emulsion method. We assessed their uptake by murine macrophage RAW264.7 cells using fluorescence microscopy. To enable real-time tracking, we conjugated p-SCN-Bn-deferoxamine to PLGA-NH2 nanoparticles and further radiolabelled them with 89Zr-oxalate before administration to mice via different routes. Nanoparticle internalisation by lung immune cells was monitored using fluorescence-activated cell sorting analysis. Results: The nanoparticle sizes were 294 ± 2.1 (small), 522.5 ± 5.58 (intermediate), and 850 ± 18.52 nm (large). Fluorescent labelling did not significantly alter the nanoparticle size and charge. The level of uptake of small and large nanoparticles by RAW264.7 cells was similar, with phagocytosis inhibition primarily reducing the internalisation of large particles. Positron emission tomography revealed that intranasal delivery resulted in the highest and most targeted pulmonary uptake, whereas intravenous administration led to accumulation mainly in the liver and spleen. Nasal delivery of large nanoparticles resulted in enhanced uptake by myeloid immune cells relative to lymphoid cells, whereas dendritic cell uptake initially peaked but declined over time. Conclusions: Our study provides valuable insights into advancing nanomedicine and drug delivery, with the potential for expanding the clinical applications of nanoparticles.

PLGA nanoparticles for nasal drug delivery

Versatile Nanoparticulate Systems as a Prosperous Platform for Targeted Nose–Brain Drug Delivery

Intranasal administration enhances size-dependent pulmonary phagocytic uptake of poly(lactic-co-glycolic acid) nanoparticles

Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery

Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases.

Progress in nasal drug delivery systems

POTENTIAL OF NANOSTRUCTURED LIPID CARRIERS IN NOSE TO BRAIN TARGETING FOR ALZHEIMER’S DISEASE

PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases

Cell-penetrating Peptide-Modified PLGA Nanoparticles for Enhanced Nose-to-brain Macromolecular Delivery

Non-Invasive Techniques of Nose to Brain Delivery Using Nanoparticulate Carriers: Hopes and Hurdles

Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery

Chances and Challenges in Intranasal Administration Delivery for Brain Disease Treatment

Review of Intranasal Active Pharmaceutical Ingredient Delivery Systems

Recent progress in nanoparticulate-based intranasal delivery for treating of different central nervous system diseases

Poly(lactic-co-glycolic acid) nanoparticle fabrication, functionalization, and biological considerations for drug delivery

Pharmacokinetics and disposition of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) nanoparticles.

Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases

Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy

Advances in polysaccharide-based formulations for intranasal drug delivery: A review